Yuhan (000100.KS) Osake Kurssi
Yuhan Kurssi
Viimeisten 19 vuoden aikana Yuhann liikevaihto kasvoi 9,0 % vuodessa ja ylsi 2,19 T KRW:een. Osakekohtainen tulos on kasvanut 5,9 % vuodessa viimeisten 19 vuoden aikana. Yuhann nettomarginaali 8,9 % on noussut verrattuna 6,1 %:iin muutama vuosi sitten. Nykyhinnalla osinkotuotto on noin 0,64 %. Jakosuhde on noin 28 % tuloksesta. Osinko on kasvanut 8,5 % vuodessa viimeisten 19 vuoden aikana. Yuhann 12 kuukauden konsensustavoitehinta on 151 980,00 KRW, noin yli kurssia 93,6 %. 20 analyytikosta 16 suosittaa ostoa — kokonaiskonsensus on Osta.
Yuhan osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Yuhan liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Yuhan -osakkeesta
The business model of Yuhan Corp revolves around its core operations in the pharmaceutical industry. As a leading South Korean company, Yuhan Corp focuses on researching, developing, manufacturing, and marketing various pharmaceutical products. Its diverse portfolio includes prescription drugs, over-the-counter medications, and medical devices. By combining innovation, cutting-edge technology, and strategic partnerships, Yuhan Corp aims to address unmet medical needs and improve the overall health and well-being of individuals. With a strong emphasis on research and development, the company continually strives to deliver high-quality and effective healthcare solutions to customers worldwide.
Yuhan Corp is primarily active in the pharmaceutical industry.
The main competitors of Yuhan Corp in the market include Hanmi Pharmaceutical Co., Ltd., CJ Healthcare Corp., and Daewoong Pharmaceutical Co., Ltd.
Yuhan Corp, a leading pharmaceutical company, has a rich and extensive history. Established in 1926, it has grown to become an integral part of the healthcare industry in South Korea. Over the years, Yuhan Corp has been committed to enhancing the well-being of individuals through innovative and high-quality healthcare products. With a diverse product portfolio covering areas such as pharmaceuticals, animal health, and personal care, Yuhan Corp has established itself as a trusted brand both domestically and internationally. Continuously adapting to market demands and leveraging its research and development capabilities, Yuhan Corp strives to contribute to the improvement of global healthcare.
Yuhan Corp has achieved several significant milestones throughout its history. Some noteworthy achievements include the successful development and launch of innovative pharmaceutical products in various therapeutic areas. The company has also established strategic partnerships with global pharmaceutical organizations, expanding its global presence and promoting international collaborations. Yuhan Corp's commitment to research and development has resulted in groundbreaking advancements and the introduction of cutting-edge technologies. Additionally, it has received recognition for its sustainable business practices and contributions to societal welfare. Overall, Yuhan Corp's remarkable milestones highlight its dedication to advancing healthcare and its continuous pursuit of excellence in the pharmaceutical industry.
Yuhan Corp is primarily present in South Korea.
Yuhan Corp represents values and corporate philosophy centered around innovation, excellence, and ethical business practices. As a leading pharmaceutical and chemical company in South Korea, Yuhan Corp strives to provide innovative solutions for various healthcare needs. With a strong commitment to research and development, the company aims to enhance the quality of life by developing and commercializing safe and effective pharmaceutical products. Yuhan Corp also emphasizes sustainability and corporate social responsibility, aiming to contribute to a healthier society and environment. With a focus on customer satisfaction and continuous improvement, Yuhan Corp remains dedicated to delivering value and advancing the healthcare industry.
Analyytikot asettavat tällä hetkellä Yuhan-osakkeelle keskimääräisen tavoitehinnan 140 165,00 KRW (mediaani: 151 980,00 KRW), mikä merkitsee +78,6 % viimeisimpään hintaan verrattuna. Konsensus perustuu 20 analyytikkoarvioon.
22 analyytikkoa arvioi tällä hetkellä Yuhan-osaketta: 18 suosittaa ostoa, 1 pitoa ja 3 myyntiä. Vuodelle 2026 analyytikot odottavat Yuhan-yhtiöltä 2,33 T KRW liikevaihtoa ja 2 643,03 KRW osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Yuhan-osake noteerataan hintaan 53,07 EUR (78 500,00 KRW).
Yuhan-osake (000100.KS) on listattuna 1 pörssissä, muun muassa: KOSPI (Seoul) (000100.KS).
Yuhan Corporation is a South Korean company that was founded in 1926 and operates in various business sectors. The company is active in the pharmaceutical, health & wellness, and chemical industries. Pharmaceuticals Yuhan Corp primarily focuses on the development and manufacturing of innovative drugs, particularly for the treatment of cancer and neurological diseases. The company is able to effectively conduct research and development as over half of its employees work in this field. In addition to the pharmaceutical industry, the company also works as a distributor for international pharmaceutical companies such as Eli Lilly and Sanofi. Health & Wellness Yuhan Corp is also active in the health and wellness industry. The company operates a comprehensive health center and offers a variety of services and products to promote the health of customers and patients. The products offered include dietary supplements, health drinks, and personal care products. Chemicals Yuhan Corp also has a business segment for chemical products. The company produces a variety of chemicals, particularly for the manufacture of authentication concepts for the electronics industry and dyes for the textile industry. The chemical division of Yuhan aims to implement sustainable production methods to develop more environmentally-friendly solutions for the industry. In summary, Yuhan Corp is a diverse company that operates in various sectors. The company has enhanced its strategies in research and development, product development, and marketing to strengthen its presence in the global market. With a combination of expertise, technological innovation, and a commitment to sustainability, Yuhan Corp has solidified its status as a leading company in the industry and will continue to do so.
odotettu liikevaihto Yuhan on 2,33 T KRW. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Yuhan on 157,06 Mrd. KRW. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Yuhan:n hinta-voitto-suhde (P/E) on tällä hetkellä 29,70. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Yuhan-osakkeen arvostusta.
Yuhan:n hinta-myynti-suhde (P/S) on tällä hetkellä 2,00. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Yuhan-osakkeen arvostuskennuslukuna.
Yuhan:n Eulpool-laatuscore on 7/10.
Yuhan:n ISIN on KR7000100008. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Yuhan:n ticker on 000100.KS. Tämä pörssinoteeraus käytetään Yuhan-osakkeiden kauppaan pörssissä.
Yuhan osake
Yuhan Ticker
Yuhan FIGI
Kaikki tunnusluvut ja syvällinen analyysi Yuhan:sta
Meidän osakeanalyysimme Yuhan-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Yuhan:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: